Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NIVOLUMAB Cause Gamma-glutamyltransferase increased? 261 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 261 reports of Gamma-glutamyltransferase increased have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.3% of all adverse event reports for NIVOLUMAB.

261
Reports of Gamma-glutamyltransferase increased with NIVOLUMAB
0.3%
of all NIVOLUMAB reports
78
Deaths
160
Hospitalizations

How Dangerous Is Gamma-glutamyltransferase increased From NIVOLUMAB?

Of the 261 reports, 78 (29.9%) resulted in death, 160 (61.3%) required hospitalization, and 29 (11.1%) were considered life-threatening.

Is Gamma-glutamyltransferase increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 261 reports have been filed with the FAERS database.

What Other Side Effects Does NIVOLUMAB Cause?

Death (11,216) Malignant neoplasm progression (9,363) Off label use (5,208) Diarrhoea (4,692) Fatigue (3,709) Pyrexia (3,454) Intentional product use issue (3,297) Rash (2,816) Nausea (2,805) Decreased appetite (2,619)

What Other Drugs Cause Gamma-glutamyltransferase increased?

FINGOLIMOD (635) ACETAMINOPHEN (442) METHOTREXATE (421) ATORVASTATIN (376) RIBOCICLIB (375) LETROZOLE (323) DEXAMETHASONE (292) CYCLOPHOSPHAMIDE (277) CARBOPLATIN (262) RITUXIMAB (242)

Which NIVOLUMAB Alternatives Have Lower Gamma-glutamyltransferase increased Risk?

NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW NIVOLUMAB vs NIZATIDINE NIVOLUMAB vs NOMEGESTROL NIVOLUMAB vs NORDAZEPAM NIVOLUMAB vs NOREPINEPHRINE

Related Pages

NIVOLUMAB Full Profile All Gamma-glutamyltransferase increased Reports All Drugs Causing Gamma-glutamyltransferase increased NIVOLUMAB Demographics